189 related articles for article (PubMed ID: 33434314)
1. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
Dempster DW; Zhou H; Rao SD; Recknor C; Miller PD; Leder BZ; Annett M; Ominsky MS; Mitlak BH
J Bone Miner Res; 2021 Apr; 36(4):644-653. PubMed ID: 33434314
[TBL] [Abstract][Full Text] [Related]
2. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao SD; Miller PD; Woodson GC; Lindsay R; Binkley N; Alam J; Ruff VA; Gallagher ER; Taylor KA
J Bone Miner Res; 2016 Jul; 31(7):1429-39. PubMed ID: 26841258
[TBL] [Abstract][Full Text] [Related]
3. Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.
Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Melby TE; Ruff VA
J Bone Miner Res; 2018 Feb; 33(2):298-306. PubMed ID: 29024120
[TBL] [Abstract][Full Text] [Related]
4. Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.
Eriksen EF; Chapurlat R; Boyce RW; Shi Y; Brown JP; Horlait S; Betah D; Libanati C; Chavassieux P
J Bone Miner Res; 2022 Jan; 37(1):36-40. PubMed ID: 34633116
[TBL] [Abstract][Full Text] [Related]
5. Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis.
Tanizawa T; Itoh A; Uchiyama T; Zhang L; Yamamoto N
Bone; 1999 Oct; 25(4):493-9. PubMed ID: 10511118
[TBL] [Abstract][Full Text] [Related]
6. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
[TBL] [Abstract][Full Text] [Related]
7. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
8. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
Dempster DW; Zhou H; Ruff VA; Melby TE; Alam J; Taylor KA
J Bone Miner Res; 2018 Apr; 33(4):627-633. PubMed ID: 29194749
[TBL] [Abstract][Full Text] [Related]
10. Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck.
Rooney AM; Dempster DW; Nieves JW; Zhou H; Bostrom MPG; Cosman F
Bone; 2022 Apr; 157():116342. PubMed ID: 35092891
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
Lewiecki EM; Czerwinski E; Recknor C; Strzelecka A; Valenzuela G; Lawrence M; Silverman S; Cardona J; Nattrass SM; Binkley N; Annett M; Pearman L; Mitlak B
J Bone Miner Res; 2023 Oct; 38(10):1404-1414. PubMed ID: 37417725
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
Ma YL; Zeng QQ; Chiang AY; Burr D; Li J; Dobnig H; Fahrleitner-Pammer A; Michalská D; Marin F; Pavo I; Stepan JJ
Bone; 2014 Feb; 59():139-47. PubMed ID: 24269280
[TBL] [Abstract][Full Text] [Related]
13. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
[TBL] [Abstract][Full Text] [Related]
15. Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab.
Dempster DW; Chines A; Bostrom MP; Nieves JW; Zhou H; Chen L; Pannacciulli N; Wagman RB; Cosman F
J Bone Miner Res; 2020 Jul; 35(7):1282-1288. PubMed ID: 32163613
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.
Chavassieux P; Portero-Muzy N; Roux JP; Horlait S; Dempster DW; Wang A; Wagman RB; Chapurlat R
J Bone Miner Res; 2019 Apr; 34(4):626-631. PubMed ID: 30601581
[TBL] [Abstract][Full Text] [Related]
17. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
Cosman F; Hans D; Shevroja E; Wang Y; Mitlak B
J Bone Miner Res; 2023 Apr; 38(4):464-470. PubMed ID: 36588166
[TBL] [Abstract][Full Text] [Related]
18. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.
Boyce RW; Niu QT; Ominsky MS
Bone; 2017 Aug; 101():77-87. PubMed ID: 28428078
[TBL] [Abstract][Full Text] [Related]
19. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
20. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Recker R; Dempster D; Langdahl B; Giezek H; Clark S; Ellis G; de Villiers T; Valter I; Zerbini CA; Cohn D; Santora A; Duong LT
J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
